Market Overview - The pharmaceutical commercial sector increased by 0.17% on October 14, with Baiyang Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 26.19, up 1.35% with a trading volume of 48,200 shares and a transaction value of 127 million [1] - China Pharmaceutical (600056) closed at 11.26, up 1.26% with a trading volume of 278,600 shares and a transaction value of 313 million [1] - Dazhenlin (603233) closed at 16.81, up 1.14% with a trading volume of 75,200 shares [1] - Other notable performers include Jianfa Zhixin (301584) up 1.01% and Renmin Tongtai (600829) also up 1.01% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 129 million from institutional investors, while retail investors saw a net inflow of 209 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are increasing their positions [2] Individual Stock Capital Flow - Saily Medical (603716) had a net inflow of 27.9 million from institutional investors, but a net outflow of 21.2 million from speculative funds [3] - Jianfa Zhixin (301584) saw a net inflow of 11.02 million from institutional investors, with a net outflow of 9.78 million from speculative funds [3] - Yifeng Pharmacy (603939) had a net inflow of 9.47 million from institutional investors, while retail investors experienced a net outflow of 13.37 million [3]

Core Insights - The medical consumables supply chain SPD sector experienced a decline of 0.4% on October 10, with Sely Medical leading the drop [1][2] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Market Performance - Notable gainers in the SPD sector included: - Dajia Weikang (11.34, +1.89%, 43,000 shares, 48.66 million CNY) - Yingte Group (11.49, +1.77%, 55,400 shares, 63.23 million CNY) - Liuyao Group (19.20, +1.75%, 121,000 shares, 231 million CNY) [1] - Sely Medical saw a significant decline, closing at 24.75, down 4.51%, with a trading volume of 142,100 shares and a transaction value of 356 million CNY [2] Capital Flow - The SPD sector experienced a net outflow of 206 million CNY from institutional investors, while retail investors saw a net inflow of 185 million CNY [2] - Key individual stock capital flows included: - Jiuzhoutong: 12.68 million CNY net inflow from institutions, but a net outflow of 15.94 million CNY from retail [3] - Liuyao Group: 9.20 million CNY net inflow from institutions, with a net outflow of 6.93 million CNY from retail [3]

Core Points - The company held its fifth extraordinary general meeting on October 9, 2025, with no resolutions being rejected [2][3] - The meeting was convened by the board of directors and chaired by Chairman Wen Wei, complying with relevant laws and regulations [3][4] - A significant resolution was passed regarding capital increase for a subsidiary and related party investment [5][6] Meeting Details - The meeting took place at the company's headquarters in Wuhan, China [2] - All nine current directors attended the meeting, along with the board secretary and other senior executives [4] Voting and Legal Oversight - The resolution regarding the subsidiary's capital increase was approved by more than half of the voting rights held by attending shareholders [6] - The meeting was witnessed by lawyers from Guohao Law Firm, confirming that the procedures and voting results were legal and valid [6] Convertible Bond Information - As of September 30, 2025, a total of 231.552 million yuan of "Saili Convertible Bonds" had been converted into ordinary shares, representing 9.3975% of the company's total share capital before conversion [8][16] - The total amount of unconverted convertible bonds as of the same date was 187.978 million yuan, accounting for 34.5987% of the total issuance [8][16] - During the third quarter of 2025, 229.833 million yuan of convertible bonds were converted, resulting in the issuance of 19.15182 million shares [8][15] Convertible Bond Issuance and Terms - The company issued 5.4331 million convertible bonds in August 2020, with a total value of 54.331 million yuan and a maturity of six years [10][11] - The initial conversion price was set at 16.98 yuan per share, with subsequent adjustments made to the conversion price over time [12][13][14]

塞力斯医疗科技集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 9 月 30 日，累计已有 23,155.2 万元"塞力 转债"转为公司普通股，累计转股股数为 19,266,619 股，占"塞力转债"转股 前公司总股本的比例为 9.3975%。 未转股可转债情况：截至 2025 年 9 月 30 日，尚未转股的"塞力转债" 金额为 18,797.8 万元，占"塞力转债"发行总量的比例为 34.5987%。 | | | 经上海证券交易所自律监管决定书【2020】306号文同意，公司发行总额为 54,331万元的可转换公司债券于2020年9月15日起在上海证券交易所挂牌交易， 债券简称"塞力转债"，债券代码"113601"。 （三）可转换公司债券转股日期及转股价格调整情况 本季度转股情况："塞力转债"自 2025 年 7 月 1 日至 2025 年 9 月 30 日期间，累计转股金额为 22,983.3 万元，因转股形成的股份数量为 1 ...

国浩律师（上海）事务所 2025 年第五次临时股东会 关 于 塞力斯医疗科技集团股份有限公司 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28th Floor, Suhe Centre, No.99 West Shanxi Road, Shanghai 200085, China 电话/Tel:+86 21 5234 1668 传真/Fax:+86 21 5243 3320 网址/Website: http://www.grandall.com.cn 2025 年 10 月 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于塞力斯医疗科技集团股份有限公司 2025 年第五次临时股东会之法律意见书 致：塞力斯医疗科技集团股份有限公司 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2025 年第五次临 时股东会于 2025 年 10 月 9 日召开。国浩律师（上海）事务所（以下简称"本 所"）经公司聘请，委派律师出席现场会议，见证公司 2025 年第五次临时股东 会（以下简称"本次股东会"）。 本所律师根据《中华人民共和国公司法》《中华人民 ...

证券代码：603716 证券简称：塞力医疗 公告编号：2025-088 塞力斯医疗科技集团股份有限公司 2025年第五次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 10 月 9 日 (二)股东会召开的地点：公司（武汉市东西湖区金山大道 1310 号）A 栋 A 会议室 | 1、出席会议的股东和代理人人数 | 1,312 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 9,206,659 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 4.4651 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由塞力斯医疗科技集团股份有限公司董事会召集，由公司董事 长温伟先生主持。本次会议的召集、召开、表决方式符合有关法律、行政法规、 部门规章和《公司章程》的有关规定。 (五)公司董事 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 27.17 | -2.96% | 5.74万 | 1.58亿 | | 301584 | C建发致 | 28.15 | -2.90% | 21.71万 | 6.15亿 | | 600833 | 第一医药 | 13.38 | -2.76% | 8.11万 | 260'T | | 301126 | 达嘉维康 | 11.13 | -2.37% | 4.04万 | 4537.69万 | | 603108 | 润达医疗 | 15.70 | -1.88% | 19.17万 | 3.00亿 | | 000705 | 浙江震元 | 9.78 | -1.41% | 13.46万 | 1.31亿 | | 002462 | 章章点 | 13.69 | -0.58% | 4.41万 | 6013.33万 | | 300937 | 药易购 | 26.53 | -0.49% | 1.29万 | 3415.25万 | | 600538 | 国发股份 ...

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [4] - Bee Assistant plans to raise no more than 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [5] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Three squirrels have received approval from the China Securities Regulatory Commission for H-share issuance, with plans to issue up to 81.5483 million shares [7] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [8] Group 2 - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind, solar, and energy storage [9] - Sains plans to invest no more than 300 million yuan in the expansion of its selection agent project [10] Group 3 - Hunan YN reports no significant changes in its internal and external operating environment [11] - Electric Power Investment has had its major asset replacement review suspended by the Shenzhen Stock Exchange due to expired financial documents [12] - Guanzhong Ecological is in the planning stage for acquiring a 51% stake in Hangzhou Actuary [13][14] Group 4 - Aima Technology's subsidiary is transferring production capacity and ceasing operations due to strategic adjustments [17] - Fosun Pharma's subsidiary has received approval for clinical trials of a new drug [18] - SAIC Group's subsidiary plans to invest 666 million yuan in the restructuring of SAIC Hongyan [19] Group 5 - Hanwei Technology plans to sell 65% of Hanwei Zhiyuan for approximately 440 million yuan [20] - Xingtong Co. has been awarded new capacity for coastal inter-provincial bulk liquid hazardous goods transportation [21][22] Group 6 - EVE Battery Investment received a cash dividend of 375 million HKD from its associate company [23] - Shanmei International's chairman has resigned due to work changes [24] - Weiye Co.'s chairman has resigned for personal reasons [25] Group 7 - Jiao Da Sino's chairman has been placed under detention [26] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [27][28] - *ST Zhengping's stock has been suspended for investigation due to abnormal price fluctuations [29] Group 8 - Zhenray Technology's chairman has had detention measures lifted [30] - Shiming Technology's chairman has had detention measures changed to a warning [31] - Nanxin Pharmaceutical is under investigation by the CSRC for suspected violations in annual report disclosures [32] Group 9 - Daqian Ecology's shareholder plans to reduce holdings by up to 3% [33] - Rundar Medical's shareholders plan to reduce holdings by up to 2.99% [34][35] - Saili Medical's shareholder plans to reduce holdings by up to 2% [36] Group 10 - Huaxin Environmental plans to repurchase shares for 40 to 80 million yuan [37] - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [38] - Zhongwu Drone has signed a significant contract worth 615 million yuan for drone systems [39]

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [2] - Bee Assistant plans to raise up to 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [3] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] Group 2 - Three squirrels received approval from the China Securities Regulatory Commission for H-share issuance, planning to issue up to 81.5483 million shares [5] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [6] - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind and solar energy [7] Group 3 - Sainz's subsidiary plans to invest up to 300 million yuan in the expansion of selection and extraction agents [8] - Hunan YN reported no significant changes in its internal and external operating environment [9] - Electric Power Investment plans to restructure assets and has received a notice from the Shenzhen Stock Exchange to suspend review [10] Group 4 - Guanzhong Ecology is in the planning stage to acquire 51% of Hangzhou Actuary [11] - Aima Technology announced the transfer and suspension of production capacity at its subsidiary in Guangdong [12] - Fosun Pharma's subsidiary received approval for clinical trials of a new drug [13] Group 5 - EVE Battery Investment received a cash dividend of 375 million HKD from its indirect associate, Simoer International [14] - Shanmei International announced a change in its board leadership due to personnel changes [15] - Weiye Co. announced the resignation of its chairman for personal reasons [16] Group 6 - Jiaoda Sinuo's chairman is under detention, and the company has appointed a new acting chairman [17] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [18] - ST Zhengping's stock price has seen an abnormal increase, leading to a suspension for investigation [19] Group 7 - Daqian Ecology's shareholder plans to reduce its stake by up to 3% [20] - Rundat Medical's shareholders plan to collectively reduce their stake by up to 2.99% [21] - Seli Medical's shareholder plans to reduce its stake by up to 2% [22] Group 8 - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [23] - Zhongwu Drone signed a significant contract worth 615 million yuan for drone systems [24]

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-087 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 持股 5%以上股东的基本情况 截至本公告披露日，上海盎泽私募基金管理有限公司-盎泽太盈六号私募证 券投资基金(以下简称"上海盎泽"）持有塞力斯医疗科技集团股份有限公司（以 下简称"公司"）12,100,399 股无限售条件流通股，占公司总股本的 5.76%（因 可转债转股导致公司总股本增加，上海盎泽的持股比例相应发生变动：截至 2025 年 6 月 30 日，公司总股本为 191,018,075 股，上海盎泽彼时持股比例为 6.33%； 截至 2025 年 8 月 20 日，公司总股本增至 210,139,246 股，上海盎泽持股比例随 之变为 5.76%。本次相关计算以截至 2025 年 8 月 ...